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Abstract
DNMT3B encodes a DNA methyltransferase implicated in aberrant epigenetic changes 
contributing to leukemogenesis. We tested whether DNMT3B expression, measured by 
NanoString nCounter assay, associates with outcome, gene- and microRNA-expression and DNA 
methylation profiles in 210 older (≥60 years) adults with primary, cytogenetically normal AML 
(CN-AML). Patients were dichotomized into high versus low expressers using median cut. 
Outcomes were assessed in the context of known CN-AML prognosticators. Gene- and 
microRNA-expression, and DNA methylation profiles were analyzed using microarrays and 
MethylCap-sequencing, respectively. High DNMT3B expressers had fewer complete remissions 
(CR; P=0.002) and shorter disease-free (DFS; P=0.02) and overall (OS; P<0.001) survival. In 
multivariable analyses, high DNMT3B expression remained an independent predictor of lower CR 
rates (P=0.04) and shorter DFS (P=0.04) and OS (P=0.001). High DNMT3B expression associated 
with a gene-expression profile comprising 363 genes involved in differentiation, proliferation and 
survival pathways, but with only 4 differentially expressed microRNAs (miR-133b, miR-148a, 
miR-122, miR-409-3p) and no differential DNA methylation regions. We conclude that high 
DNMT3B expression independently associates with adverse outcome in older CN-AML patients. 
Gene-expression analyses suggest that DNMT3B is involved in the modulation of several genes, 
although the regulatory mechanisms remain to be investigated to devise therapeutic approaches 
specific for these patients.
Keywords
acute myeloid leukemia; DNMT3B expression; prognostication; gene-expression profiling
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disease presenting with a wide spectrum 
of prognostically relevant cytogenetic aberrations, gene mutations and abnormal expression 
of genes and microRNAs. Cytogenetically normal AML (CN-AML) patients, constituting 
40 to 50% of all AML patients,1 are the largest and molecularly best characterized 
cytogenetic subset in primary (de novo) AML.1–3 Although leukemic blasts of these patients 
do not contain microscopically detectable chromosome abnormalities, they harbor 
prognostically relevant mutations and aberrantly expressed genes and microRNAs.2–16 In 
addition to these genetic alterations, epigenetic changes have recently been shown to 
participate in myeloid leukemogenesis and be pharmacologically targetable.17,18 Notably, 
some genes whose mutations are prognostic in CN-AML encode proteins that are implicated 
in epigenetic regulation of gene transcription, namely IDH2, ASXL1 and DNMT3A. The 
latter is among the most frequently mutated genes in primary CN-AML patients, being 
found mutated in 29 to 34% of the patients.9,19
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DNMT3A encodes DNA methyltransferase 3A (DNMT3A), which is involved in epigenetic 
gene silencing through DNA hypermethylation.20 In addition to DNMT3A, DNMT1 and 
DNMT3B also mediate DNA methylation in normal and malignant cells, and may represent 
potential therapeutic targets in cancer and leukemia.21–24 However, in contrast to DNMT3A, 
no recurrent mutations of DNMT1 and DNMT3B genes have been reported in AML.25 
Instead, one study has indicated that higher expression of DNMT3B is associated with worse 
outcome in AML.26 However, the patient cohort analyzed was cytogenetically diverse and 
heterogeneous for clinical features and treatment received. Thus, it is unknown whether 
DNMT3B expression is an independent prognostic factor and can be used for stratification 
guidance in CN-AML.
Thus, we analyzed the clinical significance of DNMT3B expression in the context of a 
comprehensive panel of molecular prognosticators in a relatively large cohort of older (aged 
≥60 years) patients with CN-AML who were similarly treated on cytarabine/daunorubicin-
based protocols. To gain biologic insights, we also derived genome-wide DNMT3B-
associated gene- and microRNA-expression and DNA methylation profiles. We studied 
older patients because both the incidence of AML and the role of epigenetics increase with 
age. Moreover, we have recently reported a favorable clinical response to hypomethylating 
agents in this age group of AML patients.27
PATIENTS AND METHODS
Patients, treatment and cytogenetic studies
Pretreatment bone marrow (BM) or blood samples were obtained from 210 patients with 
primary CN-AML aged 60 to 83 years (median, 68 years) who received intensive first-line 
therapy on Cancer and Leukemia Group B (CALGB) trials.28–32 All patients received 
cytarabine-daunorubicin-based induction chemotherapy, and no patient received allogeneic 
hematopoietic stem cell transplantation (HSCT) during first complete remission (CR). For 
details regarding treatment protocols and sample collection, see Supplementary Information. 
All patients were enrolled on companion CALGB/Alliance protocols: 8461 (cytogenetic 
analyses), 9665 (tissue banking) and 20202 (molecular analyses).
Cytogenetic analyses were performed in institutional CALGB/Alliance cytogenetics 
laboratories. For the patient’s karyotype to be considered normal, ≥20 metaphase cells from 
short-term cultures of pretreatment BM specimens had to have been analyzed and the 
normal result confirmed by central karyotype review.33 All patients provided written 
informed consent for participation in these studies; study protocols were in accordance with 
the Declaration of Helsinki and approved by local Institutional Review Boards.
Single-gene expression analyses
The expression of DNMT3B transcript was assessed by NanoString nCounter assays 
(NanoString Technologies, Seattle, WA, USA; Supplementary Information).34 These assays 
measured global expression of the DNMT3B gene, and did not allow for quantification of 
isoform-specific expression of DNMT3B. DNMT3B expression levels were normalized using 
ABL as an internal control. We also used NanoString nCounter assays to measure expression 
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of BAALC, ERG and miR-155, and real-time RT-PCR to measure miR-3151 expression, all 
of which have been previously shown to affect prognosis of older CN-AML patients.10,15,16
Mutational analyses
The presence or absence of FLT3 internal tandem duplication (FLT3-ITD),35,36 FLT3 
tyrosine kinase domain mutations (FLT3-TKD),37 MLL partial tandem duplication (MLL-
PTD),38 and mutations in the NPM1,5 CEBPA,39 WT1,40 IDH1 and IDH2,7 TET2,41 
ASXL1,8 DNMT3A9 and RUNX142 genes were determined centrally as previously described.
Gene- and microRNA-expression profiling
The gene- and microRNA-expression profiling were assessed using the Affymetrix U133 
plus 2.0 array (Affymetrix, Santa Clara, CA) and The Ohio State University (OSU) custom 
microRNA array (OSU_CCC Version 4.0), respectively, as previously reported,5,43 and 
detailed in the Supplementary Information. For DNMT3B, the Affymetrix U133 plus 2.0 
arrays measured global DNMT3B expression levels, and did not quantify expression of the 
individual DNMT3B isoforms. For the gene- and microRNA-expression profiling, summary 
measures of gene and microRNA expression were computed, normalized, and filtered 
(Supplementary Information). A DNMT3B expression-associated signature (see 
Supplementary Information for details) was derived by comparing gene expression between 
high and low DNMT3B expressers in the Alliance cohort and in two additional sets of CN-
AML patients with microarray and RNAseq gene expression data publicly available 
[German AML Cooperative Group (AMLCG)44 and The Cancer Genome Atlas (TCGA)25]. 
For comparison of the high DNMT3B expression signature with the FLT3-ITD signature we 
used gene set enrichment analysis (GSEA; for details see Supplementary Information). For 
the microRNA expression signature, only the CALGB/Alliance patients were used. 
Univariable significance levels of P<0.001 (false discovery rates (FDR) <0.01) were used to 
select genes and microRNAs that constituted the signatures. To assess enrichment of genes 
in the DNMT3B gene-expression-associated signature in distinct biologic processes, a Gene 
Ontology (GO) analysis was performed using the Database for Annotation, Visualization, 
and Integrated Discovery (DAVID).45 We identified as statistically significant “annotation 
clusters” those clusters of GO terms with enrichment scores of >2.0, P-values ≤0.001 and 
Benjamini corrected P-values ≤0.05. All molecular analyses were performed centrally at 
OSU.
DNA methylation
Genome-wide DNA methylation and levels of DNA methylation across the genome’s 
functional regions (i.e., genomic features) were measured using the MethylCap-seq assay as 
previously reported.18
Statistical analyses
The patients were dichotomized into high and low expressers using the median cut. This cut 
was supported by significant results of the trend test applied to outcome of patients divided 
into quartiles by DNMT3B expression (P≤0.001). We compared pretreatment features and 
outcome between patients with high and low DNMT3B expression. Definitions of clinical 
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endpoints [i.e., CR rates, disease-free (DFS) and overall (OS) survival] are provided in the 
Supplementary Information. Baseline characteristics between high and low DNMT3B 
expressers were compared using the Fisher’s exact test for categorical and the Wilcoxon 
rank-sum test for continuous variables.46 The categorical variables included the European 
LeukemiaNet (ELN) Genetic Groups.47 The ELN guidelines classify CN-AML patients 
within the Favorable or Intermediate-I Genetic Groups based on CEBPA, NPM1 and FLT3 
mutational status. The ELN Favorable Genetic Group consists of CN-AML patients with 
CEBPA mutation and/or NPM1 mutation without FLT3-ITD, whereas the Intermediate-I 
Genetic Group is comprised of patients with wild-type CEBPA and FLT3-ITD with or 
without NPM1 mutation, or wild-type NPM1 without FLT3-ITD.47
For time-to-event analyses, we calculated survival estimates using the Kaplan-Meier 
method, and compared groups by the log-rank test.46 In order to provide the odds ratios and 
hazard ratios and associated confidence intervals, logistic regression and Cox proportional 
hazards models were generated to compare outcomes between high and low DNMT3B 
expressers for CR and survival endpoints (DFS, OS), respectively, and P-values from the 
Wald test are reported. We constructed multivariable logistic regression models to analyze 
factors associated with the achievement of CR, and multivariable Cox proportional hazards 
models for factors associated with survival endpoints,46 the details of which are provided in 
the Supplementary Information. All analyses were performed by the Alliance for Clinical 
Trials in Oncology Statistics and Data Center.
RESULTS
Associations of DNMT3B expression with pretreatment clinical and molecular 
characteristics
At diagnosis, high DNMT3B expressers had higher white blood counts (WBC; P=0.004), 
and percentages of blood (P=0.004) and marrow (P=0.02) blasts than low DNMT3B 
expressers. Concerning molecular features, high DNMT3B expressers were more often 
FLT3-ITD-positive (P<0.001) and classified in the ELN Intermediate-I Genetic Group 
(P=0.02). IDH2-R140 mutations were less frequent in high DNMT3B expressers, whereas 
six of seven IDH2-R172 mutations were detected in this patient group. High DNMT3B 
expressers also had higher ERG (P<0.001), BAALC (P=0.002) and miR-155 (P=0.006) 
expression than low expressers (Table 1, Supplementary Figure S1).
Associations of DNMT3B expression with clinical outcome in the entire patient cohort
With a median follow-up for patients alive of 5.1 years (range, 2.3–11.6 years), high 
DNMT3B expressers had lower CR rates (P=0.002, Wald test; 58% vs 78%), and shorter 
DFS (P=0.02, Wald test) and OS (P<0.001, Wald test) than DNMT3B low expressers (Table 
2, Figure 1).
In a multivariable model for CR, DNMT3B expression remained prognostic (P=0.04), after 
adjustment for BAALC expression status (P<0.001), WBC (P=0.007) and age (P=0.02) 
(Table 3). High DNMT3B expressers were half as likely to achieve a CR as low expressers. 
In multivariable analysis for DFS, high DNMT3B expression associated with shorter DFS 
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(P=0.04), once adjusted for BAALC expression (P=0.004), DNMT3A-R882 mutation status 
(P=0.009) and ELN Genetic Groups (P=0.03). The risk of experiencing relapse or death was 
46% higher for high DNMT3B expressers than for low expressers. DNMT3B expression also 
remained prognostic for OS (P=0.001), after adjustment for BAALC expression (P<0.001), 
miR-3151 (P=0.02) and miR-155 (P=0.02). The risk of death was 72% higher for high 
DNMT3B expressers compared with low expressers (Table 3).
Associations of DNMT3B expression with clinical outcome in ELN genetic groups
We analyzed the associations of DNMT3B expression with outcome separately within the 
ELN Favorable and Intermediate-I Genetic Groups. Within the Favorable Group (n=94), 
there was no significant difference in CR rates (71% vs 84%, P=0.14, Wald test) or DFS 
(P=0.10, Wald test) between high and low DNMT3B expressers. However, high expressers 
had shorter OS (P=0.002, Wald test) than low expressers (Table 2, Figures 2A and 2B). In 
multivariable analyses for the ELN Favorable Genetic Group (Table 3), DNMT3B 
expression remained significant for OS (P=0.003) after adjustment for BAALC expression 
(P=0.01). High DNMT3B expressers were twice as likely to die as low expressers.
In the Intermediate-I Group (n=108), high DNMT3B expressers had a lower CR rate (49% vs 
73%, P=0.01, Wald test) and shorter OS (P=0.03, Wald test) than low DNMT3B expressers, 
but there was no significant difference in DFS between the groups (Table 2, Figures 2C and 
2D). In multivariable analyses within the ELN Intermediate-I Genetic Group (Table 3), 
DNMT3B expression was significant for OS (P=0.02), after adjustment for BAALC 
expression (P=0.03), miR-3151 expression (P=0.03) and WBC (P=0.03). High DNMT3B 
expressers were 1.7 times more likely to die than low expressers.
Genome-wide gene-expression profiles associated with DNMT3B expression
To gain biologic insights into the role of DNMT3B, we derived a DNMT3B-associated gene-
expression profile using three independent sets of CN-AML patients, i.e., CALGB/Alliance 
(n=177), AMLCG (n=75) and TCGA (n=88). We identified 195 upregulated genes and 168 
downregulated genes that were significantly associated with higher DNMT3B expression in 
each of the three cohorts (Supplementary Table S1). Since high DNMT3B expression was 
associated with the presence of FLT3-ITD (Table 1), we performed GSEA to test whether a 
set of 195 genes that are upregulated in high DNMT3B expressers is associated with a set of 
genes differentially expressed between patients who harbored FLT3-ITD versus those who 
did not (Supplementary Information). We found a significant correlation between the high 
DNMT3B expression and FLT3-ITD signatures (P=0.006; FDR=0.006; Supplementary 
Figure S2). Among the genes upregulated in high DNMT3B expressers, we noted a variety 
of genes previously involved in AML including CDK6 and WT1 that encode cyclin kinase 
and transcription factor proteins, respectively. Among the downregulated genes, we noted 
genes involved with both normal monocyte/macrophage differentiation and immune 
function including CD14, TLR4, CEBPB and TLR8.
Gene Ontology was used to assess the biologic features of the DNMT3B-expression profile 
(Table 4). For DNMT3B-associated upregulated genes, there were three GO terms 
comprising genes involved in nucleotide biosynthetic processes and metabolism and 
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included in annotation cluster 1 that had a trend for statistical significance (Benjamini P-
value <0.1). For DNMT3B-associated downregulated genes, cellular processes included 
lysosome biology, endocytosis and membrane signaling. These results may be interpreted as 
consistent with the previously noted dysregulated genes involved in monocyte/macrophage 
differentiation and activity.
Genome-wide microRNA profiles associated with DNMT3B expression
The influence of DNMT3B expression on microRNA genome-wide profiles could be 
evaluated in 162 patients. In contrast to coding genes, only four microRNAs were 
differentially expressed between high and low DNMT3B expressers (P≤0.001). High 
DNMT3B expression was associated with miR-133b upregulation, and miR-148a, miR-122 
and miR-409-3p downregulation. miR-133b upregulation in high DNMT3B expressers was 
somewhat surprising as this microRNA was reported to have tumor suppressor activity in 
other cancers.48,49 However, consistent with the downregulated gene-expression profile 
discussed above, miR-133b has recently been shown to target GM-CSF, a cytokine involved 
in granulocyte-monocyte/macrophage differentiation.50 Among the downregulated 
microRNAs, miR-148a was reported to target DNMT3B and to be itself a target of aberrant 
hypermethylation in cancer.51,52 Lower expression of miR-122 has been associated with 
aggressive hepatocellular carcinoma and miR-409-3p with cell invasion and metastasis in 
gastric cancer53–56; however, a role for these microRNAs in AML is currently unknown.
Genome-wide methylation profiling associated with DNMT3B expression
Since DNMT3B encodes a methyltransferase that mediates de novo DNA methylation, we 
assessed whether high and low DNMT3B expressers differed in DNA methylation patterns. 
Surprisingly, we found no significant differences in genome-wide DNA methylation levels 
or in the numbers of differentially methylated regions (DMRs)18 in distinct functional 
genomic regions (e.g., gene promoters) when high versus low DNMT3B expressers were 
compared.
DISCUSSION
In this study, we report that high DNMT3B expression associates with lower CR rates and 
shorter DFS and OS in chemotherapy-treated CN-AML patients aged ≥60 years. High 
DNMT3B expression was associated with such adverse prognostic factors as FLT3-ITD, 
high ERG, BAALC and miR-155 expression and the ELN Intermediate-I Genetic Group; 
nevertheless the association of DNMT3B expression with clinical outcome is independent 
from the aforementioned and other established molecular and clinical prognosticators for all 
outcome endpoints studied.
Our findings are consistent to some extent with the only, to our knowledge, previous study 
that assessed the prognostic value of DNMT3B expression.26 Although in the subset of 93 
CN-AML patients, Hayette et al.26 did not find significant differences in event-free survival 
(EFS) or OS between high and low DNMT3B expressers, high DNMT3B expressers had a 
shorter EFS than low DNMT3B expressers in the whole cytogenetically diverse cohort of 
191 AML patients analyzed. It is difficult to directly compare their results with ours since 
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approximately one-half of the patients analyzed by Hayette et al.26 had various abnormal 
karyotypes, more than two-thirds of the patients were younger than 60 years and a quarter 
underwent allogeneic HSCT in first CR. Thus, although the two studies are not comparable, 
they both conclude that higher DNMT3B expression is associated with worse outcome in 
AML.
Recently, the ELN Reporting System,47 which for CN-AML is based on only three 
molecular markers (i.e., FLT3-ITD, CEBPA and NPM1 mutations), was shown to provide 
important prognostic information in AML.57 However, we and others have shown that 
additional molecular markers, such as TET2,41 ASXL1,8 RUNX142 and DNMT3A58 
mutations and expression of MN1,12 miR-15515 and miR-3151,16 may refine outcome 
prediction of CN-AML patients within the ELN Genetic Groups. Hence, in the current 
study, we investigated whether considering DNMT3B expression as a novel prognosticator 
could alter patient classification within the ELN Genetic Groups. In the Favorable Group, 
we found that low DNMT3B expression identified a subset of CN-AML patients with a 
significantly longer OS, thus making DNMT3B expression the third molecular marker, in 
addition to ASXL1 mutations8 and miR-155 expression,15 capable of refining prognostication 
of older patients in this ELN Genetic Group. We also observed a significant difference in 
OS between high and low DNMT3B expressers classified in the ELN Intermediate-I Genetic 
Group. Previously, RUNX1 mutations42 and expression levels of MN1,12 miR-15515 and 
miR-315116 were demonstrated to add prognostic information in this ELN Genetic Group.
We report the first, to our knowledge, DNMT3B-associated gene- and microRNA-expression 
and DNA methylation profiles in CN-AML. We were able to derive a strong gene 
expression profile comprising 363 genes by overlapping the microarray results from three 
independent sets of patients. The profile was quite heterogeneous, comprising genes 
encoding for proteins involved in multiple biologic processes that play a role in leukemia 
cell differentiation, proliferation and survival. Among the downregulated genes, we noted 
enrichment of genes involved in monocyte/macrophage differentiation and activity, 
suggesting a role of DNMT3B in impairing differentiation of the leukemic blasts into cells 
with normal innate immunity activity. Using GSEA, we found a significant correlation 
between the high DNMT3B expression and FLT3-ITD signatures (Supplementary Figure 
S2). This, along with the increased frequency of FLT3-ITD in high DNMT3B expressers 
(Table 1), suggests the existence of a functional association between high expression of the 
DNMT3B gene and FLT3-ITD.
In contrast, the DNMT3B-associated microRNA profile was relatively weak, comprising 
only four microRNAs that were differentially expressed in high versus low DNMT3B 
expressers. Nevertheless, the unique upregulation of expression of miR-133b, recently 
reported to target GM-CSF,50 in DNMT3B high expressers was somewhat consistent with 
the enrichment of the gene-expression profile in multiple downregulated genes involved in 
the differentiation and activity of hematopoietic cells participating in innate immunity.
Surprisingly, despite the fact that DNMT3B encodes a DNA methyltransferase, we observed 
no significant association of high DNMT3B levels and DNA methylation changes. No 
difference in global DNA methylation levels and number of DMRs could be identified 
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between DNMT3B high and low expressers. Our results are reminiscent of a recent report 
showing that changes in DNMT3B expression did not affect methylation levels of putative 
DNMT3B target genes.59 Moreover, Russler-Germain et al.60 have recently demonstrated 
that DNA methylation levels in leukemic blasts from CN-AML patients are not influenced 
by DNMT3B expression since mainly inactive splice variants of DNMT3B are expressed in 
these cells. Overall, therefore, these data may suggest that although overexpressed DNMT3B 
is a potentially valuable predictive marker for response to conventional chemotherapy, it 
does not necessarily identify subsets of older AML patients characterized by aberrant DNA 
methylation who might be responsive to hypomethylating azanucleosides.
In summary, we have demonstrated that DNMT3B expression constitutes an independent 
prognostic factor in older CN-AML patients treated intensively, and could also refine the 
ELN classification. Furthermore, we have provided some insights into the biologic activity 
of DNMT3B in CN-AML, which is seemingly independent from mechanisms of DNA 
hypermethylation and/or microRNA-dependent gene repression. Further studies focused on 
gaining more clinical and mechanistic insights into the leukemogenic role of DNMT3B 
expression are warranted to design active therapeutic strategies for high DNMT3B 
expressers in CN-AML.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGEMENTS
The Cancer and Leukemia Group B institutions, and their principal investigators participating in this study are 
provided in the Supplementary Information. We thank Donna Bucci and the CALGB/Alliance Leukemia Tissue 
Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and 
storage services; Lisa J. Sterling and Chris Finks for data management; and The Ohio State University 
Comprehensive Cancer Center’s Nucleic Acid and Microarray Shared Resources for technical support. This work 
was supported in part by the National Cancer Institute (grants CA101140, CA114725, CA140158, CA31946, 
CA33601, CA16058, CA77658, and CA129657), the Coleman Leukemia Research Foundation, the Pelotonia 
Fellowship Program (A.-K.E.), the Conquer Cancer Foundation (J.H.M.) and the Deutsche Krebshilfe–Dr Mildred 
Scheel Cancer Foundation (H.B.).
REFERENCES
1. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004; 
18:115–136. [PubMed: 15010150] 
2. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations 
and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we 
ready for a prognostically prioritized molecular classification? Blood. 2007; 109:431–448. 
[PubMed: 16960150] 
3. Walker A, Marcucci G. Molecular prognostic factors in cytogenetically normal acute myeloid 
leukemia. Expert Rev Hematol. 2012; 5:547–558. [PubMed: 23146058] 
4. Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, et al. FLT3 internal 
tandem duplication associates with adverse outcome and gene- and microRNA expression 
signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid 
leukemia: a Cancer and Leukemia Group B study. Blood. 2010; 116:3622–3626. [PubMed: 
20656931] 
5. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, et al. Favorable 
prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute 
Niederwieser et al. Page 9
Leukemia. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and 
Leukemia Group B study. J Clin Oncol. 2010; 28:596–604. [PubMed: 20026798] 
6. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, et al. Mutations of the 
Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid 
leukemia: a Cancer and Leukemia Group B study. Blood. 2010; 116:788–792. [PubMed: 20442368] 
7. Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D, et al. IDH1 and IDH2 
gene mutations identify novel molecular subsets within de novo cytogenetically normal acute 
myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28:2348–2355. 
[PubMed: 20368543] 
8. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrózek K, et al. ASXL1 
mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML 
within the ELN Favorable genetic category. Blood. 2011; 118:6920–6929. [PubMed: 22031865] 
9. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, et al. Age-related 
prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically 
normal acute myeloid leukemia. J Clin Oncol. 2012; 30:742–750. [PubMed: 22291079] 
10. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, et al. BAALC and 
ERG expression levels are associated with outcome and distinct gene- and microRNA expression 
profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer 
and Leukemia Group B study. Blood. 2010; 116:5660–5669. [PubMed: 20841507] 
11. Heuser M, Beutel G, Krauter J, Döhner K, von Neuhoff N, Schlegelberger B, et al. High 
meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with 
normal cytogenetics. Blood. 2006; 108:3898–3905. [PubMed: 16912223] 
12. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrózek K, Maharry K, et al. Low 
expression of MN1 associates with better treatment response in older patients with de novo 
cytogenetically normal acute myeloid leukemia. Blood. 2011; 118:4188–4198. [PubMed: 
21828125] 
13. Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional 
role of microRNAs in acute myeloid leukemia. Blood. 2011; 117:1121–1129. [PubMed: 
21045193] 
14. Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, et al. Prognostic 
significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute 
myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28:5257–5264. 
[PubMed: 21079133] 
15. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu Y-Z, Mrózek K, et al. Clinical role of 
microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation 
independently identifies high-risk patients. J Clin Oncol. 2013; 31:2086–2093. [PubMed: 
23650424] 
16. Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, et al. miR-3151 
interplays with its host gene BAALC and independently affects outcome of patients with 
cytogenetically normal acute myeloid leukemia. Blood. 2012; 120:249–258. [PubMed: 22529287] 
17. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, et al. Epigenetics meets 
genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 
2014; 32:548–556. [PubMed: 24378410] 
18. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, et al. Genome-wide 
methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012; 
120:2466–2474. [PubMed: 22786882] 
19. Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, et al. Prognostic 
significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid 
leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012; 26:1247–1254. 
[PubMed: 22289988] 
20. Hervouet E, Vallette FM, Cartron PF. Dnmt3/transcription factor interactions as crucial players in 
targeted DNA methylation. Epigenetics. 2009; 4:487–499. [PubMed: 19786833] 
Niederwieser et al. Page 10
Leukemia. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
21. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 
impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes 
Dev. 2012; 26:344–349. [PubMed: 22345515] 
22. Li KK, Luo LF, Shen Y, Xu J, Chen Z, Chen SJ. DNA methyltransferases in hematologic 
malignancies. Semin Hematol. 2013; 50:48–60. [PubMed: 23507483] 
23. Wang J, Walsh G, Liu DD, Lee JJ, Mao L. Expression of ΔDNMT3B variants and its association 
with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. Cancer 
Res. 2006; 66:8361–8366. [PubMed: 16951144] 
24. Hlady RA, Novakova S, Opavska J, Klinkebiel D, Peters SL, Bies J, et al. Loss of Dnmt3b 
function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J Clin 
Invest. 2012; 122:163–177. [PubMed: 22133874] 
25. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo 
acute myeloid leukemia. New Engl J Med. 2013; 368:2059–2074. [PubMed: 23634996] 
26. Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, et al. High DNA 
methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. PLoS 
One. 2012; 7:e51527. [PubMed: 23251566] 
27. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, et al. Clinical response and 
miR-29b predictive significance in older AML patients treated with a 10-day schedule of 
decitabine. Proc Natl Acad Sci U S A. 2010; 107:7473–7478. [PubMed: 20368434] 
28. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive 
postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994; 
331:896–903. [PubMed: 8078551] 
29. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al. Granulocyte-
macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary 
acute myelogenous leukemia. N Engl J Med. 1995; 332:1671–1677. [PubMed: 7760868] 
30. Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, et al. Parallel phase I 
studies of daunorubicin given with cytarabine and etoposide with or without the multidrug 
resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute 
myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol. 1999; 
17:2831–2839. [PubMed: 10561359] 
31. Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, et al. Escalation of 
daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients 
aged 60 years and older: Cancer and Leukemia Group B study 9720. Leukemia. 2011; 25:800–
807. [PubMed: 21321569] 
32. Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz JE, et al. A phase III randomized trial 
of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 
antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. J Clin 
Oncol. 2007; 25(suppl):360s. (abstract 7012). 
33. Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, et al. Central review of 
cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute 
leukemia: the Cancer and Leukemia Group B experience. Int J Oncol. 2008; 33:239–244. 
[PubMed: 18636143] 
34. Payton JE, Grieselhuber NR, Chang LW, Murakami M, Geiss GK, Link DC, et al. High throughput 
digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J 
Clin Invest. 2009; 119:1714–1726. [PubMed: 19451695] 
35. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-
type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal 
cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. 
Cancer Res. 2001; 61:7233–7239. [PubMed: 11585760] 
36. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-
activating mutations in 979 patients with acute myelogenous leukemia: association with FAB 
subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99:4326–4335. 
[PubMed: 12036858] 
Niederwieser et al. Page 11
Leukemia. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
37. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of 
D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001; 
97:2434–2439. [PubMed: 11290608] 
38. Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, et al. Long-term disease-
free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem 
duplication: a Cancer and Leukemia Group B study. Blood. 2007; 109:5164–5167. [PubMed: 
17341662] 
39. Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, et al. 
Prognostic significance of gene and microRNA expression signatures associated with, CEBPA 
mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a 
Cancer and Leukemia Group B study. J Clin Oncol. 2008; 26:5078–5087. [PubMed: 18809607] 
40. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K, et al. Wilms' tumor 1 
gene mutations independently predict poor outcome in adults with cytogenetically normal acute 
myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2008; 26:4595–4602. 
[PubMed: 18559874] 
41. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, et al. TET2 
mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: 
a Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29:1373–1381. [PubMed: 21343549] 
42. Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, et al. RUNX1 
mutations are associated with poor outcome in younger and older patients with cytogenetically 
normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J 
Clin Oncol. 2012; 30:3109–3118. [PubMed: 22753902] 
43. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, et al. MicroRNA 
expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358:1919–
1928. [PubMed: 18450603] 
44. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, et al. An 86-
probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid 
leukemia. Blood. 2008; 112:4193–4201. [PubMed: 18716133] 
45. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists 
using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44–57. [PubMed: 19131956] 
46. Vittinghoff, E.; Glidden, DV.; Shiboski, SC.; McCulloch, CE. Regression Methods in Biostatistics: 
Linear, Logistic, Survival and Repeated Measures Models. New York, NY, USA: Springer; 2005. 
47. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and 
management of acute myeloid leukemia in adults: recommendations from an international expert 
panel, on behalf of the European LeukemiaNet. Blood. 2010; 115:453–474. [PubMed: 19880497] 
48. Zhao H, Li M, Li L, Yang X, Lan G, Zhang Y. MiR-133b is down-regulated in human 
osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes 
apoptosis. PLoS One. 2013; 8:e83571. [PubMed: 24391788] 
49. Duan F-T, Qian F, Fang K, Lin K-Y, Wang W-T, Chen Y-Q. miR-133b, a muscle-specific 
microRNA, is a novel prognostic marker that participates in the progression of human colorectal 
cancer via regulation of CXCR4 expression. Mol Cancer. 2013; 12:164. [PubMed: 24330809] 
50. Sturrock A, Mir-Kasimov M, Baker J, Rowley J, Paine R 3rd. Key role of microRNA in the 
regulation of granulocyte macrophage colony-stimulating factor expression in murine alveolar 
epithelial cells during oxidative stress. J Biol Chem. 2014; 289:4095–4105. [PubMed: 24371146] 
51. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b 
protein coding region. RNA. 2008; 14:872–877. [PubMed: 18367714] 
52. Zhu A, Xia J, Zuo J, Jin S, Zhou H, Yao L, et al. MicroRNA-148a is silenced by hypermethylation 
and interacts with DNA methyltransferase 1 in gastric cancer. Med Oncol. 2012; 29:2701–2709. 
[PubMed: 22167392] 
53. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-
inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012; 122:2871–
2883. [PubMed: 22820288] 
Niederwieser et al. Page 12
Leukemia. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
54. Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum 
microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular 
carcinoma. Eur J Cancer. 2013; 49:3442–3449. [PubMed: 23810247] 
55. Li A, Song W, Qian J, Li Y, He J, Zhang Q, et al. MiR-122 modulates type I interferon expression 
through blocking suppressor of cytokine signaling 1. Int J Biochem Cell Biol. 2013; 45:858–865. 
[PubMed: 23348614] 
56. Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D, et al. MicroRNA-409 suppresses tumour cell 
invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene. 2012; 31:4509–
4516. [PubMed: 22179828] 
57. Mrózek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, et al. Prognostic 
significance of the European LeukemiaNet standardized system for reporting cytogenetic and 
molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012; 30:4515–4523. 
[PubMed: 22987078] 
58. Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, et al. Clinical impact of 
DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML 
Study Group (AMLSG). Blood. 2013; 121:4769–4777. [PubMed: 23632886] 
59. Hagemann S, Kuck D, Stresemann C, Prinz F, Brueckner B, Mund C, et al. Antiproliferative 
effects of DNA methyltransferase 3B depletion are not associated with DNA demethylation. PLoS 
One. 2012; 7:e36125. [PubMed: 22563479] 
60. Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, et al. The 
R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by 
blocking its ability to form active tetramers. Cancer Cell. 2014; 25:442–454. [PubMed: 24656771] 
Niederwieser et al. Page 13
Leukemia. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Clinical outcome of CN-AML patients with high and low DNMT3B expression. Kaplan-
Meier survival curves for (a) disease-free survival and (b) overall survival. P-values 
presented are from the log rank test.
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Figure 2. 
Clinical outcome of CN-AML patients with high and low DNMT3B expression classified 
into European LeukemiaNet (ELN) Genetic Groups. Kaplan-Meier survival curves for (a) 
disease-free survival and (b) overall survival of patients in the ELN modified Favorable 
Genetic Group; (c) disease-free survival and (d) overall survival of patients in the ELN 
Intermediate-I Genetic Group. P-values presented are from the log rank test.
Niederwieser et al. Page 16
Leukemia. Author manuscript; available in PMC 2015 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Niederwieser et al. Page 17
Table 1
Comparison of clinical and molecular characteristics of patients with cytogenetically normal acute myeloid 
leukemia with high versus low DNMT3B expression
Characteristic High DNMT3B
(n=105)
Low DNMT3B
(n=105)
P
Age, years 0.82
  Median 68 68
  Range 60–83 60–81
Sex, n (%) 0.58
  Male 58 (55) 53 (50)
  Female 47 (45) 52 (50)
Race, n (%) 0.48
  White 96 (92) 92 (89)
  Nonwhite 8 (8) 11 (11)
Hemoglobin, g/dl 0.71
  Median 9.4 9.3
  Range 6.5–12.4 5.4–15.0
Platelet count, × 109/l 0.87
  Median 68 71
  Range 4–850 11–510
WBC, × 109/l 0.004
  Median 43.7 21.8
  Range 1.0–450.0 0.8–249.3
Blood blasts, % 0.004
  Median 64 40
  Range 0–99 0–97
Bone marrow blasts, % 0.02
  Median 72 64
  Range 21–97 4–97
Extramedullary involvement, n (%) 27 (27) 24 (23) 0.63
NPM1, n (%) 0.31
  Mutated 67 (66) 60 (59)
  Wild-type 34 (34) 42 (41)
FLT3-ITD, n (%) <0.001
  Present 54 (53) 21 (21)
  Absent 48 (47) 81 (79)
CEBPA, n (%) 0.83a
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Characteristic High DNMT3B
(n=105)
Low DNMT3B
(n=105)
P
  Mutated 13 (13) 12 (12)
    Single mutated 10 5
    Double mutated 3 7
  Wild-type 88 (87) 90 (88)
ELN Genetic Groupb, n (%) 0.02
  Modified Favorable 38 (38) 56 (55)
  Intermediate-I 63 (62) 45 (45)
FLT3-TKD, n (%) 0.83
  Present 12 (12) 11 (11)
  Absent 89 (88) 91 (89)
WT1, n (%) 0.41
  Mutated 8 (8) 5 (5)
  Wild-type 93 (92) 97 (95)
TET2, n (%) 1.00
  Mutated 32 (32) 31 (32)
  Wild-type 68 (68) 67 (68)
MLL-PTD, n (%) 1.00
  Present 5 (6) 5 (6)
  Absent 74 (94) 81 (94)
IDH1, n (%) 0.18
  Mutated 14 (14) 8 (8)
  Wild-type 86 (86) 94 (92)
IDH2, n (%) 0.05
  Mutated 18 (18) 31 (30)
    R140 12 30 0.005c
    R172 6 1 0.13d
  Wild-type 82 (82) 71 (70)
RUNX1, n (%) 0.31
  Mutated 17 (18) 11 (12)
  Wild-type 79 (82) 81 (88)
ASXL1, n (%) 0.69
  Mutated 13 (13) 15 (15)
  Wild-type 87 (87) 84 (85)
DNMT3A 0.65
  Mutated 35 (35) 31 (32)
    R882 19 20 1.00e
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Characteristic High DNMT3B
(n=105)
Low DNMT3B
(n=105)
P
    Non-R882 16 11 0.40f
  Wild-type 64 (65) 66 (68)
ERG expression group,g,h n (%) <0.001
  High 65 (62) 40 (38)
  Low 40 (38) 65 (62)
BAALC expression group,g,h n (%) 0.002
  High 64 (61) 41 (39)
  Low 41 (39) 64 (61)
miR-155 expression group,g,h n 
(%)
0.006
  High 63 (60) 42 (40)
  Low 42 (40) 63 (60)
miR-3151 expression group,g,i n 
(%)
0.76
  High 42 (49) 39 (46)
  Low 43 (51) 46 (54)
Abbreviations: ELN, European LeukemiaNet; FLT3-ITD, internal tandem duplication of the FLT3 gene; FLT3-TKD, tyrosine kinase domain 
mutation in the FLT3 gene; MLL-PTD, partial tandem duplication of the MLL gene; n, number; WBC, white blood count.
a
The P-value pertains to a comparison of frequencies of CEBPA mutations (single and double combined) versus CEBPA wild-type between high 
and low DNMT3B expressers.
b
The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated CEBPA and/or mutated NPM1 without FLT3-ITD. All 
remaining CN-AML patients (i.e., those with wild-type CEBPA and wild-type NPM1 with or without FLT3-ITD, or mutated NPM1 with FLT3-
ITD) belong to the ELN Intermediate-I Genetic Group.47
c
The P-value pertains to a comparison of frequencies of IDH2-R140 mutations versus IDH2 wild-type between high and low DNMT3B expressers.
d
The P-value pertains to a comparison of frequencies of IDH2-R172 mutations versus IDH2 wild-type between high and low DNMT3B expressers.
e
The P-value pertains to a comparison of frequencies of DNMT3A-R882 mutations versus DNMT3A wild-type between high and low DNMT3B 
expressers.
f
The P-value pertains to a comparison of frequencies of DNMT3A non-R882 mutations versus DNMT3A wild-type between high and low DNMT3B 
expressers.
g
The median expression value was used as a cut point.
h
Data was assessed by the NanoString nCounter assay.
i
Data was assessed by real-time RT-PCR.
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Table 2
Outcomes of patients with cytogenetically normal acute myeloid leukemia according to DNMT3B expression 
status
Endpoint High DNMT3B
(I)
Low DNMT3B
(II) P
a OR/HR
(95% CI)
I vs II
All patients n=105 n=105
  Complete remission, n (%) 61 (58) 82 (78) 0.002 0.39 (0.21–0.71)
  Disease-free survival 0.02 1.55 (1.09–2.20)
    Median, years 0.6 1.1
    % Disease-free at 3 years (95% CI) 13 (6–23) 22 (14–31)
    % Disease-free at 5 years (95% CI) 11 (5–21) 15 (8–23)
  Overall survival <0.001 1.85 (1.38–2.47)
    Median, years 0.8 1.5
    % Alive at 3 years (95% CI) 11 (6–18) 29 (20–37)
    % Alive at 5 years (95% CI) 8 (4–14) 21 (14–29)
Patients in the ELN modified Favorable Genetic Groupb n=38 n=56
  Complete remission, n (%) 27 (71) 47 (84) 0.14 0.47 (0.17–1.28)
  Disease-free survival 0.10 1.54 (0.92–2.57)
    Median, years 0.9 1.3
    % Disease-free at 3 years (95% CI) 15 (5–30) 30 (18–43)
    % Disease-free at 5 years (95% CI) 11 (3–26) 21 (11–34)
  Overall survival 0.002 2.04 (1.29–3.22)
    Median, years 1.3 2.1
    % Alive at 3 years (95% CI) 18 (7–31) 39 (27–52)
    % Alive at 5 years (95% CI) 12 (4–24) 30 (19–43)
Patients in the ELN Intermediate-I Genetic Groupb n=63 n=45
    Complete remission, n(%) 31 (49) 33 (73) 0.01 0.35 (0.15–0.80)
  Disease-free survival 0.25 1.36 (0.81–2.27)
    Median, years 0.5 0.7
    % Disease-free at 3 years (95% CI) 13 (4–27) 9 (2–22)
    % Disease-free at 5 years (95% CI) 13 (4–27) 3 (0–13)
  Overall survival 0.03 1.57 (1.06–2.33)
    Median, years 0.6 1.1
    % Alive at 3 years (95% CI) 8 (3–16) 16 (7–28)
    % Alive at 5 years (95% CI) 6 (2–14) 9 (3–19)
Abbreviations: CI, confidence interval; ELN, European Leukemia Net; HR, hazard ratio; n, number; OR, odds ratio.
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a
P-values provided are generated by logistic regression and Cox proportional hazards models to compare outcome of patients for CR and survival 
endpoints (DFS, OS), respectively, using the Wald test.
b
The ELN modified Favorable Genetic Group is defined as CN-AML patients with mutated CEBPA and/or mutated NPM1 without FLT3-ITD. All 
remaining CN-AML patients (i.e., those with wild-type CEBPA and wild-type NPM1 with or without FLT3-ITD, or mutated NPM1 with FLT3-
ITD) belong to the ELN Intermediate-I Genetic Group.47
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Table 4
Gene Ontology terms associated with differentially expressed genes in the high DNMT3B expression group
Biologic process or cellular component Number of
genes
Benjamini
P-value
Associations with genes upregulated in the high DNMT3B expression group
Annotation Cluster 1.
GOTERM_BP: nucleotide biosynthetic process 10 0.098
GOTERM_BP: nucleobase, nucleoside and nucleotide biosynthetic process 10 0.066
GOTERM_BP: nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process 10 0.066
Associations with genes downregulated in the high DNMT3B expression group
Annotation Cluster 1
GOTERM_CC: vacuole 12 0.0052
GOTERM_CC: lytic vacuole 10 0.012
GOTERM_CC: lysosome 10 0.012
Annotation Cluster 2
GOTERM_BP: endocytosis 11 0.0091
GOTERM_BP: membrane invagination 11 0.0091
GOTERM_BP: membrane organization 12 0.089
Annotation Cluster 3
GOTERM_CC: intrinsic to membrane 74 0.028
Abbreviations: GO, Gene Ontology, see also Huang da et al.45; BP, biologic process; CC, cellular component.
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